Spectrum Acquires Worldwide License to EndothelinB Agonists

Spectrum Pharmaceuticals announced that it has acquired an exclusive worldwide license to develop and commercialize endothelinB agonists for the treatment of cancer, including treatment of solid tumors, from Chicago Labs Inc., a privately held company. Chicago Labs licensed the technology and related patents from the University of Illinois.
Yahoo News